Yokozawa T, Zhou J J, Hattori M, Inaba S, Okada T, Oura H, Nonaka G, Nishioka I
Research Institute for Wakan-Yaku, Toyama Medical and Pharmaceutical University, Japan.
Nihon Jinzo Gakkai Shi. 1995 Feb;37(2):105-11.
Magnesium lithospermate B, a compound newly isolated from Dan Shen, was given orally to rats for 70 days after excision of five-sixths of their kidney volume. As a result, mesangial proliferation, tubulo-interstitial lesions and glomerular sclerotic lesions, which were conspicuous in rats that were not given magnesium lithospermate B after nephrectomy, were inhibited. Furthermore, a decrease in blood urea nitrogen, improvement of hypoproteinemia, hypoalbuminemia and hypercholesteremia, and inhibition of urinary protein excretion were observed. The levels of creatinine, methylguanidine and guanidino-succinic acid, which accumulate in the blood with the progress of renal failure, were decreased significantly in rats given magnesium lithospermate B. These results indicate that magnesium lithospermate B, a component of an Oriental medicine has potential as a new therapeutic agent for inhibiting the progression of renal dysfunction.
丹酚酸B镁是从丹参中新分离出的一种化合物，在切除大鼠六分之五的肾脏体积后，对其进行70天的口服给药。结果发现，肾切除后未给予丹酚酸B镁的大鼠中明显的系膜增殖、肾小管间质病变和肾小球硬化病变受到抑制。此外，还观察到血尿素氮降低、低蛋白血症、低白蛋白血症和高胆固醇血症得到改善，以及尿蛋白排泄受到抑制。在给予丹酚酸B镁的大鼠中，随着肾衰竭进展而在血液中积累的肌酐、甲基胍和胍基琥珀酸水平显著降低。这些结果表明，作为一种中药成分的丹酚酸B镁具有作为抑制肾功能障碍进展的新型治疗剂的潜力。
